Prikaz osnovnih podataka o dokumentu
Development and Validation of an HPLC Method for Determination of Ziprasidone and Its Impurities in Pharmaceutical Dosage Forms
dc.creator | Pavlović, Marija | |
dc.creator | Malešević, Marija | |
dc.creator | Nikolić, Katarina | |
dc.creator | Agbaba, Danica | |
dc.date.accessioned | 2019-09-02T11:25:29Z | |
dc.date.available | 2019-09-02T11:25:29Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1060-3271 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1561 | |
dc.description.abstract | Ziprasidone is known as a novel "atypical" or "second-generation" antipsychotic drug. A sensitive and reproducible method was developed and validated for determination of ziprasidone and its major impurities, which are significantly different in polarity. The separation is performed on a Waters Spherisorb (R) octadecylsilyl 1 column (5.0 mu m particle size, 250 x 4.6 mm id) using a gradient with mobile phase A [buffer acetonitrile (80+20, v/v)] and mobile phase B [buffer acetonitrile (10+90, v/v)] at a working temperature of 25 degrees C. The buffer was 0.05 M KH(2)PO(4) solution with an addition of 10 mL triethylamine/L solution, adjusted to pH 2.5 with orthophosphoric acid. The flow rate was 1.5 mL/min, and the eluate was monitored at 250 nm using a diode array detector. Optimization of the experimental conditions was performed using partial least squares regression, for which four factors were selected for optimization: buffer concentration, buffer pH, triethylamine concentration, and temperature. The proposed validated method is convenient and reliable for the assay and purity control in both raw materials and dosage forms. | en |
dc.publisher | AOAC Int, Gaithersburg | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172033/RS// | |
dc.rights | restrictedAccess | |
dc.source | Journal of AOAC International | |
dc.title | Development and Validation of an HPLC Method for Determination of Ziprasidone and Its Impurities in Pharmaceutical Dosage Forms | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Павловић, Марија; Малесевић, Марија; Николић, Катарина; Aгбаба, Даница; | |
dc.citation.volume | 94 | |
dc.citation.issue | 3 | |
dc.citation.spage | 713 | |
dc.citation.epage | 722 | |
dc.citation.other | 94(3): 713-722 | |
dc.citation.rank | M22 | |
dc.identifier.wos | 000291775400004 | |
dc.identifier.pmid | 21796998 | |
dc.identifier.scopus | 2-s2.0-80051949346 | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_farfar_1561 | |
dc.type.version | publishedVersion |
Dokumenti
Datoteke | Veličina | Format | Pregled |
---|---|---|---|
Uz ovaj zapis nema datoteka. |